Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precipio, Inc. (PRPO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly reports, and other key documents filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed healthcare biotechnology company focused on cancer diagnostics, Precipio uses these filings to report on its financial performance, capital structure, and significant corporate events.
Investors can review Precipio’s periodic reports, such as its Quarterly Reports on Form 10-Q, which the company references in its earnings press releases. These filings contain detailed information on revenues from the pathology services and products divisions, gross margin trends, cash flow from operations, and non-GAAP measures such as EBITDA and Adjusted EBITDA, along with reconciliations to GAAP results. They also provide additional context on operating expenses, investments in laboratory and manufacturing capacity, and other factors influencing profitability.
Precipio’s current reports on Form 8-K highlight material events and investor communications. Recent 8-K filings have covered topics such as the termination of an at-the-market Sales Agreement with A.G.P./Alliance Global Partners, shareholder update calls, and the posting of an updated investor presentation. These filings often include press releases or presentation materials as exhibits, giving investors direct access to management’s commentary and strategic updates.
Through its filings, Precipio also discloses information about financing arrangements, warrant exercises, and debt obligations. For example, the company has reported on the termination of its ATM facility, the extent of shares sold under that agreement, and changes in its warrant structure. Press releases referenced in filings further describe the repayment of a Change Healthcare advance and the remaining small loan with the Connecticut Department of Economic and Community Development, providing insight into the company’s debt profile.
On Stock Titan, these SEC documents are supplemented by AI-powered tools that help interpret complex filings. Investors can use AI-generated summaries to understand the main points of lengthy 10-Q or 10-K reports, track Form 8-K events, and quickly identify disclosures related to revenue composition, margins, capital structure changes, and other topics relevant to a specialty cancer diagnostics company like Precipio.
Precipio, Inc. reported net sales of $5.65 million for the three months ended June 30, 2025, up from $4.44 million a year earlier, led by service revenue of $5.005 million versus $3.909 million. Gross profit for the quarter was $2.43 million compared with $1.72 million in the prior year. The company recorded net income of $74 thousand in the quarter versus a $1.22 million loss in Q2 2024; for the six months it reported a net loss of $810 thousand compared with a $3.30 million loss a year earlier. A material contributor to quarterly other income was a recorded Employee Retention Credit of approximately $789 thousand.
The balance sheet shows total assets of $18.82 million, cash of $1.13 million and an accumulated deficit of $103.3 million. Management discloses substantial doubt about the company’s ability to continue as a going concern for the next twelve months absent additional revenue or financing. Material items disclosed include purchase commitments of approximately $2.2 million, a CHC temporary funding balance of about $0.6 million to be repaid through January 2026, and customer concentration with one customer representing ~27% of net sales.